Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists

Journal of Managed Care & Specialty Pharmacy
Yehuda HandelsmanDoron Schneider

Abstract

This article provides an overview of the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic GLP-1 receptors, which increases insulin secretion, delays gastric emptying, and increases satiety. As a class, GLP-1 RAs lower A1c levels and have been associated with reductions in weight and blood pressure and reduced fluctuations in glucose levels, and they have a low risk of hypoglycemia. Exenatide extended release (ER) and dulaglutide monotherapy have shown similar or superior reductions in A1c and weight compared with various oral antidiabetic drugs (OADs). Semaglutide has been shown to reduce both A1c and body weight compared with placebo and, in head-to-head studies versus both exenatide ER and dulaglutide, showed greater reductions in A1c and body weight. Once-weekly GLP-1 RAs have also been evaluated as add-on therapy in the continuum of care for the treatment of T2DM in combination with a variety of background medications, including 1 or more OADs (metformin, sulfonylureas, and/or thiazolidinediones), basal insulin, and prandial insulin. Gastrointestinal adverse events (e.g., nausea, vomiting, and diarrhea...Continue Reading

References

Jun 25, 2014·Diabetes Research and Clinical Practice·W D StrainP M Paldánius
Aug 15, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Annachiara UccellatoreAntonio Ceriello
Oct 30, 2015·Diabetes, Obesity & Metabolism·Sten Madsbad
Feb 18, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sheena KayaniyilBernt Kartman
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Feb 6, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lei QinSusan Grandy
Apr 25, 2017·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Philip A LevinSeoyoung C Kim
Apr 27, 2017·Annals of Pediatric Endocrinology & Metabolism·Seungah Lee, Dong Yun Lee
May 4, 2017·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Lawrence BlondeUNKNOWN Global Partnership for Effective Diabetes Management
Feb 6, 2018·The Lancet. Diabetes & Endocrinology·Richard E PratleyUNKNOWN SUSTAIN 7 investigators

❮ Previous
Next ❯

Citations

Jul 19, 2019·Clinical Drug Investigation·Katherine A Lyseng-Williamson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.